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Tumor necrosis factor alpha (TNF-) is a key mediator of host immune and inflammatory responses and
inhibits herpesvirus replication by cytolytic and noncytolytic mechanisms. TNF- effects are primarily medi-
ated through the major TNF- receptor, TNF-R1, which is constitutively expressed in most cell types. Here we
show that the Epstein-Barr virus (EBV) immediate-early protein BZLF1 prevents TNF- activation of target
genes and TNF--induced cell death. These effects are mediated by down-regulation of the promoter for
TNF-R1. Additionally, we demonstrate that expression of TNF-R1 is downregulated during the EBV lytic
replication cycle. Thus, EBV has developed a novel mechanism for evading TNF- antiviral effects during lytic
reactivation or primary infection.
Epstein-Barr virus (EBV) is a ubiquitous human -herpes-
virus that infects the majority of the world population. Primary
infection with EBV occurs in the oropharynx via saliva ex-
change and causes the syndrome infectious mononucleosis
(31). Additionally, EBV is associated with several B-cell and
epithelial-cell malignancies. Following initial infection, EBV
establishes a lifelong infection of the host by latently infecting
B cells. However, the virus undergoes periodic spontaneous
reactivation, resulting in lytic replication and release of virus
into the saliva for transmission to new hosts.
EBV lytic infection is initiated by the expression of two
immediate-early (IE) genes, BZLF1 and BRLF1 (32). The
BZLF1 gene product (called BZLF1, Zta, ZEBRA, or EB1) is
a member of the basic leucine zipper family of DNA binding
proteins that binds to AP-1-like sites, termed Z response ele-
ments, present in EBV IE and early gene promoters. BZLF1
functions as a transcriptional transactivator and, along with
BRLF1, induces the lytic cascade of viral gene expression.
The host response to viral infection includes the elaboration
of antiviral cytokines, such as tumor necrosis factor alpha
(TNF-) and interferons. TNF- is secreted by macrophages,
lymphocytes, natural killer (NK) cells, and epithelial cells.
TNF- induces a wide range of genes that play a role in the
immune and inflammatory response, including major histo-
compatibility complex (MHC) molecules, adhesion molecules,
chemokines, and cytokines (37). In addition, TNF- plays a
role in host defense by induction of cellular apoptosis and has
been demonstrated to act as a potent antiviral cytokine that is
directly cytotoxic to cells infected with both RNA and DNA
viruses, including herpesviruses (26, 40). In vitro, TNF- has
been shown to inhibit the replication of herpes simplex virus,
varicella-zoster virus, and cytomegaloviruses (6, 16, 23). Addi-
tionally, administration of neutralizing anti-TNF- antibodies
leads to increased herpes simplex virus type 1 (19) and murine
cytomegalovirus titers in vivo (10). However, the most com-
pelling evidence of the importance of TNF- in antiviral de-
fense is the wide variety of mechanisms evolved by viruses to
circumvent the effects of TNF- (3).
Cellular responses to TNF- are elicited by two distinct
receptors, TNR receptor 1 (TNF-R1) and TNF-R2 (37). These
receptors have sequence homology in their extracellular ligand
binding domains; however, the intracellular sequences are
mostly unique. TNF-R1 contains a death domain (DD), dis-
tinguishing this TNF receptor subtype as a member of the
death receptor family. The DD promotes the recruitment of
the adaptor protein TNF-R1-associated DD protein
(TRADD) (14). TRADD then serves to recruit other adaptor
proteins, including TNF-R-associated factor 2 (TRAF2), re-
ceptor-interacting protein (RIP), and Fas-associated DD pro-
tein (FADD) (12, 13). Recruitment of RIP and TRAF2 leads
to activation of NF-B and AP-1, whereas recruitment of
FADD can lead to the recruitment and activation of caspase-8
and ultimately the activation of downstream effector caspases,
such as caspase 3, and induction of apoptosis (20, 21, 36, 41).
In this report, we demonstrate that BZLF1 prevents cellular
responses to TNF-, including TNF--induced gene expres-
sion and, most importantly, TNF--induced cell death. Al-
though the TNF-R1 is constitutively expressed in essentially all
cell types, we show that BZLF1 downregulates TNF-R1 pro-
moter activity, thus eliminating TNF-R1 expression at the
RNA and protein levels. Thus, inhibition of TNF-R1 promoter
activity represents a novel mechanism for attenuating TNF-
responsiveness in cells. Finally, we demonstrate that TNF-R1
is downregulated during reactivation of the EBV lytic cycle.
To investigate whether BZLF1 inhibits TNF--induced gene
expression, telomerase-immortalized human keratinocytes
(hTERT-HFK) (5) and A549 cells were mock-infected or in-
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fected with adenovirus vectors expressing either the LacZ gene
(AdlacZ) or the BZLF1 gene (AdZ) (38), and at 30 h postin-
fection cells were left untreated or treated with TNF- (10
ng/ml) for 12 h. Cells were lysed in radioimmunoprecipitation
assay lysis buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1%
Nonidet P-40, 0.5% deoxycholate, 0.1% sodium dodecyl sul-
fate supplemented with complete protease inhibitor cocktail
[Roche]), and proteins were separated on a polyacrylamide
gel. Immunoblot analysis was performed with an antibody di-
rected against intracellular adhesion molecule-1 (ICAM-1) (1:
500; Santa Cruz Biotechnology) (15) or -actin (1:5,000;
Sigma). In mock-infected and AdlacZ-infected hTERT-HFK
and A549 cells, TNF- treatment induced expression of the
cell adhesion glycoprotein ICAM-1 (Fig. 1). In contrast, TNF-
-induced ICAM-1 expression was significantly inhibited in
AdZ-infected cells (Fig. 1A and 1B). These results suggest that
BZLF1 interferes with TNF--induced cellular gene expres-
sion.
An important downstream effect of TNF- signaling is the
induction of apoptosis, which allows the elimination of virus-
infected cells. To investigate the ability of BZLF1 to abolish
this critical arm of TNF-R1 signaling, A549 cells were mock
infected or infected with either AdlacZ or AdZ and at 36 h
postinfection were left untreated or treated with 15 g of
cycloheximide (CHX) per ml alone or CHX in combination
with TNF- (10 ng/ml) for 4 h. Immunoblot analysis was per-
formed with an antibody directed against caspase-3 (1:200
from Santa Cruz Biotechnology) or -actin (1:5,000 from
Sigma). As expected, in both mock infected and AdlacZ-in-
fected cells CHX–TNF- treatment resulted in decreased
amounts of procaspase-3 (the full-length, unactivated form of
the enzyme) (Fig. 2A) and the appearance of the cleaved,
active forms of the enzyme (Fig. 2B). Treatment with CHX
alone had no effect on caspase-3 activation (Fig. 2A and B). In
contrast, expression of BZLF1 inhibited the cleavage of pro-
caspase-3 (Fig. 2A) and the appearance of the cleaved, active
forms of caspase-3 induced by the combination treatment (Fig.
2B), suggesting that the activation of caspases associated with
TNF--induced apoptosis is inhibited by BZLF1.
The effectiveness of BZLF1 expression in blocking apoptosis
induced by TNF- was measured by treating A549 cells as
described above and determining cell viability by trypan blue
exclusion assay. As shown in Fig. 3, treatment of mock-infected
and AdlacZ-infected A549 cells with the combination of CHX
plus TNF- for 12 h resulted in averages of 38 and 34% cell
death, respectively. BZLF1 expression reduced the amount of
cell death induced by the combination treatment to an average
FIG. 1. BZLF1 inhibits TNF--induced gene expression. hTERT-
HFK (A) and A549 (B) cells were mock infected or infected with
adenovirus expressing LacZ or BZLF1 (MOI of 30). At 30 h postin-
fection, cells were left untreated or treated with 10 ng of recombinant
TNF- per ml for 12 h. Immunoblot analysis was performed with
anti-ICAM-1 and anti--actin antibodies.
FIG. 2. BZLF1 inhibits TNF--induced caspase 3 activation. A549
cells were mock infected or infected with adenovirus expressing LacZ
or BZLF1 (MOI of 30). At 36 h postinfection, cells were left untreated,
treated with CHX alone (15 g/ml), or treated with CHX (15 g/ml)
plus 10 ng of recombinant TNF- per ml for 4 h. Immunoblot analysis
was performed for the full-length proenzyme form of caspase-3
(A) and for the cleaved, active forms of capase-3 (p17 and p12) (B).
Immunoblots were reprobed with anti--actin antibodies as a loading
control.
FIG. 3. BZLF1 protects A549 cells from TNF--induced cell death.
A549 cells were mock infected or infected with adenovirus expressing
LacZ or BZLF1 (MOI of 30). At 36 h postinfection, cells were left
untreated, treated with CHX alone (15 g/ml), or treated with CHX
(15 g/ml) plus 10 ng of recombinant TNF- per ml for 12 h. Apo-
ptosis was assayed as a function of cell viability and measured by trypan
blue exclusion assay.
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of 10%. Additionally, AdZ-infected cells showed increased
sensitivity to CHX treatment alone (Fig. 3), suggesting that the
amount of cell death induced via TNF-R1 signaling might in
fact be further reduced.
To determine at what point BZLF1 inhibits the TNF-R1
signaling pathway, TNF-R1 expression was quantitated by im-
munoblot analysis (using anti-TNF-R1 [1:200] from Santa
Cruz) in hTERT-HFK, A549, and HeLa cells that were mock
infected or infected with either AdlacZ or AdZ. In all cell lines
tested, expression of BZLF1 dramatically decreased the pro-
tein level of TNF-R1 (Fig. 4A). This decrease was not due to
induction of TNF- by AdZ, as analysis of hTERT-HFK and
A549 cell culture supernatants by TNF- ELISA was negative
for all groups (data not shown). Importantly, as previously
published, the level of cellular BZLF1 expression in hTERT-
HFK, A549, and HeLa cells infected with AdZ at the multi-
plicity of infection (MOI) used in these experiments is similar
to the level of BZLF1 expressed in the lytically infected pop-
ulation of an epithelial cell line (AGS) infected with the intact
virus (25, 27). To confirm that the BZLF1-induced decrease of
TNF-R1 expression is not an adenovirus-mediated effect, im-
munoblot analysis was also performed on HeLa cells and A549
cells that had been transfected with a BZLF1 expression plas-
mid. Cells were seeded into six-well plates 1 day prior to
transfection. One microgram of plasmid DNA was combined
with 3 l of FuGENE 6 transfection reagent (Roche) in Op-
tiMEM (Invitrogen) and added directly to cell cultures, and
cell extracts were prepared 48 h posttransfection. As shown in
Fig. 4B, BZLF1 expression from plasmid DNA also decreased
TNF-R1 expression in each of these cell types.
To determine if decreased TNF-R1 expression is due to a loss
of the TNF-R1 message, we examined the effect of BZLF1 on
TNF-R1 RNA expression. Total RNA was isolated from hTERT-
HFK and A549 cells by using an RNeasy kit (Qiagen) following
the manufacturer’s instructions, and cDNA was synthesized with
a reverse transcription system (Promega). Semiquantitative PCR
was performed by using serial dilutions of input cDNA with the
following oligonucleotides: TNFR1, sense, 5-GTGCCAACAA
AGGAACCTACTTGTAC-3 (spans exon 2 and 3 of genomic
sequence); antisense, 5-GGCCAGGGGCTTAGTAGTAGTT
C-3 (within exon 9 of genomic sequence); 2-microglobulin,
sense, 5-TTCTGGCCTGGAGGGCATCC-3 (within exon 1 of
genomic sequence); antisense, 5-ATCTTCAAACCTCCATGA
TG-3 (within exon 3 of genomic sequence). Semiquantitative
reverse transcription-PCR analysis revealed that the level of
TNF-R1 RNA was greatly reduced in cells that expressed BZLF1
(Fig. 4C and D). The level of a control transcript, 2-microglobu-
lin, was unaffected by expression of BZLF1 (Fig. 4C and D).
Taken together, these results indicate that expression of BZLF1
dramatically decreases cellular expression of TNF-R1 and suggest
that the decrease may be a BZLF1-mediated transcriptional ef-
fect.
FIG. 4. BZLF1 decreases TNF-R1 protein and RNA levels. (A) hTERT-HFK, HeLa, and A549 cells were mock infected or infected with
adenovirus (MOI of 50) expressing either LacZ or BZLF1 for 48 h. Immunoblot analysis was performed with anti-TNF-R1 and anti--actin
antibodies. (B) A549 and HeLa cells were transfected with a vector control or a BZLF1 expression plasmid. At 48 h posttransfection, cell lysates
were examined by immunoblot analysis with anti-TNF-R1, anti-BZLF1, and anti--actin antibodies. HTERT-HFK (C) and A549 (D) cells were
mock infected or infected with adenovirus (MOI of 50) expressing either LacZ or BZLF1. Semiquantitative reverse transcription-PCR analysis was
performed by using serial dilutions of input cDNA with oligonucleotide primers specific for TNF-R1 mRNA sequences or with primers for
2-microglobulin sequences.
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A great deal of research has focused on posttranscriptional
and posttranslational regulation of TNF-R1; in contrast, very
little is known about the regulation of the TNF-R1 promoter. A
5 region upstream of the TNF-R1 start codon has been shown
to encode promoter activity, and the transcriptional start sites
have been determined (18). In order to investigate the effect of
BZLF1 on TNF-R1 promoter activity, a TNF-R1–CAT re-
porter plasmid was constructed by PCR cloning of a 654-bp
region from the human genome corresponding to the 619/
35 region of the TNF-R1 promoter (relative to the major
transcriptional start site), as previously defined (18). These
sequences were inserted upstream of the chloramphenicol
acetyltransferase (CAT) reporter gene, and the resulting plas-
mid was used in cotransfection assays. At 48 h posttransfection,
cells were lysed directly in 0.25 M Tris, pH 7.5. Aliquots of cell
extracts were incubated at 37°C with [14C]chloramphenicol in
the presence of acetyl coenzyme A. Acetylated forms of chlor-
amphenicol were resolved by thin-layer chromatography, and
the percent acetylation of chloramphenicol was quantitated by
PhosphorImager screening (Molecular Dynamics). The TNF-
R1–CAT construct had significant constitutive activity in HeLa
cells relative to the promoterless CAT vector control (Fig. 5A).
Furthermore, cotransfection of the TNF-R1–CAT construct
with a BZLF1 expression vector dramatically reduced TNF-R1
promoter activity (Fig. 5A). Similar results were obtained with
A549 cells (data not shown).
We next determined the domains of the BZLF1 protein
required to inhibit TNF-R1 promoter activity by cotransfecting
the TNF-R1–CAT reporter plasmid with various BZLF1 wild-
type and mutant expression plasmids into HeLa cells. Plasmids
pSG5-Zwt and pSG5-ZA185K were constructed by subcloning
wild-type BZLF1 cDNA or A185K BZLF1 cDNA (containing
a point mutation that alters amino acid 185 from alanine to
lysine) from the pHD1013 vector (29) into the EcoRI site of
pSG5 (Stratagene). Plasmid pSG5-Z	TA was generated by
HindIII cleavage of pSG5-Zwt followed by religation, produc-
ing an in-frame deletion of amino acids 24 to 86. As shown in
Fig. 5C, a BZLF1 mutant unable to bind DNA due to a single
amino acid change at residue 185 in the DNA binding domain
completely lost the ability to inhibit TNF-R1 promoter activity.
Additionally, removal of amino acids 24 to 86, which deletes
the BZLF1 transactivation domain, abolished the ability of
BZLF1 to inhibit TNF-R1 promoter activity (Fig. 5C). Immu-
noblot analysis confirmed similar expression levels of wild-type
and mutant BZLF1 proteins, as depicted in one representative
blot in Fig. 5D. These results indicate that BZLF1 downregu-
lates TNF-R1 expression by inhibiting TNF-R1 promoter ac-
tivity.
To determine whether TNF-R1 is downregulated during
EBV lytic replication, we generated EBV-infected gastric car-
cinoma cell lines. AGS-EBV cells were generated by infecting
gastric carcinoma AGS cells with a recombinant EBV that
contains a gene encoding green fluorescent protein and a hy-
gromycin resistance cassette (a gift from Henri J. Delecluse)
(7). EBV-positive cells were selected with 100 g of hygromy-
cin B per ml. EBV is associated with up to 10% of human
gastric carcinomas (35), and lytic cycle antigens, including
BZLF1, have been detected in tumor cells, indicating that lytic
EBV infection occurs in EBV-positive gastric carcinomas (11).
EBV-negative and EBV-positive AGS cells were treated with
50 ng of phorbol myristate acetate per ml and 1 mM butyrate
for 24 h. As shown in Fig. 6, treatment of AGS-EBV cells
resulted in high-level expression of both BZLF1 and the early
gene BMRF1 from the endogenous EBV genome, indicating
FIG. 5. BZLF1 inhibits TNF-R1 promoter activity. (A) HeLa cells
were transfected with 500 ng of vector control or BZLF1 expression
plasmids along with 500 ng of pBS-CAT or TNF-R1–CAT reporter
plasmids. At 48 h posttransfection, cells were harvested and extracts
analyzed for CAT activity. (B) A schematic depicting the structures of
the wild-type and mutant BZLF1 proteins is shown. The transactiva-
tion domain (TA), DNA binding domain (DNA), and dimerization
domain (DIM) are indicated along with the respective amino acid
numbers. (C) HeLa cells were transfected with 500 ng of vector control
or various BZLF1 expression plasmids along with 500 ng of the TNF-
R1–CAT reporter plasmid. wt, wild type. (D) Immunoblot analysis was
performed to confirm equal expression of BZLF1 wild-type and mu-
tant proteins in extracts used for panel C.
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that the virus had entered the lytic replication cycle. TNF-R1
expression was significantly decreased in AGS-EBV cells in-
duced to enter the lytic replication cycle (Fig. 6), while the
expression of TNF-R1 in the parental AGS cells was not af-
fected by treatment with the lytic-cycle-inducing agents (Fig.
6). These results suggest that expression of TNF-R1 is down-
regulated in cells lytically infected with EBV.
In this paper, we report that the EBV IE protein BZLF1
inhibits cellular responses to TNF- by downregulating expres-
sion of TNF-R1. Additionally, we have found that BZLF1
downregulates TNF-R1 expression by inhibiting TNF-R1 pro-
moter activity. To our knowledge, this is the first report de-
scribing regulation of TNF-R1 by a viral protein at the pro-
moter level.
The fact that other DNA viruses encode functions that di-
rectly antagonize TNF-R1 activity suggests an important role
for this receptor in antiviral defenses. Recently, both HCMV
(2) and murine cytomegalovirus (28) have been shown to tar-
get TNF-R1. Additionally, poxvirus, adenovirus, and human
papillomavirus (8, 30, 34) also target TNF-R1 signaling. Our
finding that BZLF1 downregulates the TNF-R1 promoter rep-
resents a novel mechanism used by a virus to inhibit the action
of this receptor.
TNF- induces a wide array of molecules, such as cytokines,
MHC, and adhesion molecules, which mediate the inflamma-
tory response and regulate immune cell function. Thus, the
ability of BZLF1 to inhibit TNF--induced gene expression,
including ICAM-1, may be an important mechanism to limit
immune responses to viral infection.
Importantly, we also found that BZLF1 inhibits the induc-
tion of cell death by TNF-. Because apoptosis induced by
death receptor family members, such as TNF-R1, plays a key
role in the host response to viral infection, our data suggest
that inhibition of TNF-R1-induced apoptosis by BZLF1 may
protect virus-infected cells, allowing the virus to complete its
replication cycle.
TNF-R1 is constitutively expressed on most cell types (22,
33) and thought to be regulated primarily via posttranscrip-
tional (39) and posttranslational mechanisms. In particular,
shedding of a soluble form of the TNF-R1 protein plays a key
role in attenuating TNF- effects (9). To date, however, few
studies have focused on regulation of the TNF-R1 promoter.
Mutational analysis of BZLF1 revealed that inhibition of
TNF-R1 promoter activity requires both the transactivation
and the DNA binding domains of BZLF1. These results sug-
gest that BZLF1 may bind to and activate the promoter of a
gene that encodes a repressor of the TNF-R1 promoter. Less
likely, BZLF1 may bind directly to the TNF-R1 promoter and
prevent expression.
Interestingly, our lab reported previously that expression of
BZLF1 also downregulates a component of the cellular recep-
tor for gamma interferon (IFN-), IFN--R, and likewise
inhibits cellular responses to IFN- (27). Thus, downregulation
of TNF-R1, together with downregulation of IFN--R, by
BZLF1 may prolong the life of a lytically infected cell and
enhance virus production.
In summary, this report describes a novel mechanism to
regulate expression of TNF-R1 and inhibit the cellular re-
sponses to TNF-. These data, together with previous reports
that BZLF1 induces immunosuppressive cytokines such as in-
terleukin 10 and transforming growth factor beta (4, 24), in-
hibits cellular responses to IFN- (27), and disperses nuclear
promyelocytic leukemia bodies (1) and the recent report that
BZLF1 inhibits upregulation of MHC class I expression by the
viral protein LMP1 (17), provide compelling evidence that
BZLF1 plays a major role in viral subversion of host immune
responses.
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